Pharmaniaga

Pharmaniaga Berhad (Pharmaniaga) is a Malaysian pharmaceutical company. It is a subsidiary of Boustead Holdings, an affiliate of the Malaysian military.

Pharmaniaga Berhad

Company type	Public limited company
Traded as	MYX: 7081
Industry	Pharmaceuticals Health care
Predecessor	Southern Task (M) Sdn Bhd (1994) Remedi Pharmaceuticals (1994-1998)
Founded	1994 (1994)
Founder	UEM Group
Headquarters	Shah Alam, Selangor, Malaysia
Area served	Worldwide
Key people	Zulkifli Jafar, Managing Director; Ahmad Shahredzuan Mohd Shariff, Chief Operating Officer; Norai’ni Mohamed Ali, Chief Financial Officer; Idham Ismail, Chief Strategy Officer; Dr Badarulhisam Abdul Rahman, Scientific Officer and Wan Intan Idura Wan Ismail, Chief Governance Officer
Products	Prescription drugs, over-the-counter drugs, biopharmaceuticals
Revenue	RM3,404,481,000 (FY2023)
Net income	RM78,744,000 (FY2023)
Number of employees	Over 3,400
Parent	Boustead Holdings
Subsidiaries	Pharmaniaga Logistics Sdn Bhd Pharmaniaga Marketing Sdn Bhd Pharmaniaga Research Centre Sdn Bhd Pristine Pharma Sdn Bhd (ceased operation) Paradigm Industry Sdn Bhd (ceased operation) Pharmaniaga Manufacturing Bhd Idaman Pharma Manufacturing Sdn Bhd (Sungai Petani) Idaman Pharma Manufacturing Sdn Bhd (Seri Iskandar) Pharmaniaga LifeScience Sdn Bhd PT Millennium Pharmacon International TBK PT Errita Pharma
Website	www.pharmaniaga.com

History

Pharmaniaga was established in 1994 as Remedi Pharmaceuticals. The company was renamed as Pharmaniaga in August 1998 and is the first healthcare company in Malaysia to be listed in the Main Market of Kuala Lumpur Stock Exchange (now Bursa Malaysia).

Ownership

Pharmaniaga is a public limited company. Its two major shareholders are Boustead Holdings and Lembaga Tabung Angkatan Tentera (LTAT). The major owner of Boustead Holdings is itself LTAT.

The Company's Board Members comprise Dato’ Seri Abdul Razak Jaafar, Independent Non-Executive Chairman; Zulkifli Jafar, Managing Director; Dr Abdul Razak Ahmad, Senior Independent Non-Executive Director; Izaddeen Daud, Non-Independent Non-Executive Director; Sarah Azreen Abdul Samat, Independent Non-Executive Director; Mohammad Ashraf Md. Radzi, Non-Independent Non-Executive Director; Dato’ Mohd Zahir Zahur Hussain, Independent Non-Executive Director; Dato’ Dr Faridah Aryani Md Yusof, Independent Non-Executive Director; Drs Imam Fathorrahman, Independent Non-Executive Director; Dr Mary Jane Cardosa, Independent Non-Executive Director; Dato’ Seri Dr Awaludin Said, Independent Non-Executive Director and Mohd Firdaus Zulkifli, Non-Independent Non-Executive Director (Alternate Director to Mohammad Ashraf Md. Radzi).

Business Overview

Pharmaniaga's expertise extends beyond manufacturing, encompassing logistics and distribution, as well as dynamic sales and marketing strategies that ensure their products reach those in need nationwide.

Pharmaniaga has over 3,400 employees, and more than 200 scientific and technical experts across various disciplines.

With five manufacturing plants, including Indonesia plant, Pharmaniaga is capable of producing products in various forms; from oral solids, liquids and creams to small volume injectables.  Its product portfolio encompasses a diverse segment of therapeutic areas such as cardiovascular, diabetes, anti-infectives, pain management, and respiratory, amongst others.

Its Indonesia operations comprise of PT Errita Pharma (Errita) and PT Millennium Pharmacon International Tbk (MPI). MPI is a public listed company on the Indonesia Stock Exchange with 35 branches nationwide. Meanwhile, Errita produces over 60 generic pharmaceuticals as well as over-the-counter products.